JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Home・Aandelen Lijst・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Gesloten

SectorGezondheidszorg

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-0.05% downside

Mirati Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 apr 2026, 23:47 UTC

Marktinformatie

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 apr 2026, 23:43 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 apr 2026, 23:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

23 apr 2026, 23:43 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 apr 2026, 23:13 UTC

Acquisities, Fusies, Overnames

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 apr 2026, 22:33 UTC

Winsten

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 apr 2026, 22:17 UTC

Winsten

PLS Executed Offtake Agreement With Ronbay

23 apr 2026, 22:17 UTC

Winsten

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 apr 2026, 22:16 UTC

Winsten

PLS Commences Commissioning of Midstream Demonstration Plant

23 apr 2026, 22:15 UTC

Winsten

PLS Group Reaffirms FY26 Guidance for All Metrics

23 apr 2026, 22:14 UTC

Winsten

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 apr 2026, 22:14 UTC

Winsten

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 apr 2026, 22:13 UTC

Winsten

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 apr 2026, 22:12 UTC

Winsten

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 apr 2026, 22:12 UTC

Winsten

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 apr 2026, 22:11 UTC

Winsten

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 apr 2026, 22:10 UTC

Winsten

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 apr 2026, 22:09 UTC

Winsten

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 apr 2026, 22:08 UTC

Winsten

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 apr 2026, 22:04 UTC

Winsten

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 apr 2026, 21:56 UTC

Marktinformatie

Winsten

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 apr 2026, 21:48 UTC

Acquisities, Fusies, Overnames

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 apr 2026, 21:27 UTC

Winsten

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 apr 2026, 21:25 UTC

Winsten

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 apr 2026, 21:24 UTC

Winsten

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 apr 2026, 21:24 UTC

Winsten

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 apr 2026, 21:21 UTC

Winsten

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 apr 2026, 21:21 UTC

Winsten

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

23 apr 2026, 21:18 UTC

Winsten

Intel Stock Soars on Strong Earnings and Strong Outlook -- Barrons.com

23 apr 2026, 21:17 UTC

Winsten

Intel CEO: Foundry Business Remains a Long Journey

Peer Vergelijking

Prijswijziging

Mirati Therapeutics Inc Prognose

Koersdoel

By TipRanks

-0.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.67 USD -0.05%

Hoogste 59 USD

Laagste 58 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Mirati Therapeutics Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

Over Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.